Solid polyglycol-based biocompatible pre-formulation

Abstract

Provided herein are pre-formulations forming a biocompatible hydrogel polymer comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the biocompatible hydrogel polymer covers a wound in a mammal and adheres to the surrounding skin tissue. In other embodiments, the hydrogel polymer is delivered into a joint space to treat joint disease or navicular disease.

1 - 15 . (canceled) 
     
     
         16 . A would healing solid polyglycol-based, fully synthetic, pre-formulation, comprising: (a) at least one solid first compound comprising more than two nucleophilic groups; (b) at least one solid second compound comprising more than two electrophilic groups; (c) optionally, a solid buffer component; (d) optionally, a therapeutic agent; and (e) optionally, a solid viscosity enhancer,
 wherein the solid polyglycol-based, fully synthetic, pre-formulation polymerizes and/or gels at a target site of the wound to form a polyglycol-based, fully synthetic, biocompatible hydrogel polymer after addition of a liquid component,   wherein the liquid component does not contain any first compound or second compound, and provided that the solid polyglycol-based, fully synthetic, pre-formulation does not contain any aqueous component.   
     
     
         17 . The wound healing solid polyglycol-based, fully synthetic, pre-formulation, wherein the therapeutic is a solid therapeutic agent. 
     
     
         18 . The wound healing solid polyglycol-based, fully synthetic, pre-formulation, wherein the liquid component comprises water, saline, a buffer, a therapeutic agent, or a combination thereof. 
     
     
         19 . The wound healing solid polyglycol-based, fully synthetic, pre-formulation, wherein the solid first compound is a MULTIARM (5k-50k) polyol derivative comprising polyglycol subunits and more than two nucleophilic groups, and wherein the solid second compound is a MULTIARM (5k-50k) polyol derivative comprising polyglycol subunits and more than two electrophilic groups. 
     
     
         20 . The wound healing solid polyglycol-based, fully synthetic, pre-formulation, wherein the solid first compound is a MULTIARM-(5-50k)-SH, a MULTIARM-(5-50k)-NH2, a MULTIARM-(5-50k)-AA, or a combination thereof, and the solid second compound is a MULTIARM-(5-50k)-SG, a MULTIARM-(5-50k)-SGA, a MULTIARM-(5-50k)-SS, or a combination thereof. 
     
     
         21 . The wound healing solid polyglycol-based, fully synthetic, pre-formulation, wherein the solid first compound is 4ARM-5k-SH, 4ARM-2k-NH2, 4ARM-5k-NH2, 8ARM-20k-NH2, 4ARM-20k-AA, 8ARM-20k-AA, or a combination thereof, and the solid second compound is 4ARM-10k-SG, 8ARM-15k-SG, 4ARM-20k-SGA, 4ARM-10k-SS, or a combination thereof. 
     
     
         22 . The wound healing solid polyglycol-based, fully synthetic, pre-formulation, wherein the solid first compound is 8ARM-20k-NH2 and/or 8ARM-20k-AA, and the solid second compound is 4ARM-20k-SGA.